The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.
Livestrong.com on MSN6d
Phenylephrine for Colds: Why It Doesn’t Work and What You Should Use InsteadDiscover why oral phenylephrine in cold medicine is ineffective for relieving congestion. Learn which alternative treatments ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
Johnson & Johnson's nasal spray received US FDA approval The nasal spray is used for the treatment of major depressive disorder The drug brought in sales of $780 million in 2024 The US Food and Drug ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...
Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback